查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018835

人類免疫力缺乏病毒（HIV）治療市場：依藥物類別、治療方法、治療階段、給藥途徑、病患類型及通路分類－2026-2032年全球市場預測

Human Immunodeficiency Virus Therapeutics Market by Drug Class, Regimen Type, Therapy Line, Mode Of Administration, Patient Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人類免疫力缺乏病毒 (HIV) 治療市場價值將達到 212.3 億美元，到 2026 年將成長到 222.3 億美元，到 2032 年將達到 293.2 億美元，複合年成長率為 4.71%。

主要市場統計數據
基準年 2025 212.3億美元
預計年份：2026年 222.3億美元
預測年份 2032 293.2億美元
複合年成長率 (%) 4.71%

引言部分闡述了塑造現代 HIV 治療策略的臨床進展、政策趨勢和相關人員的需求。

在不斷發展的愛滋病治療領域，亟需一個入門框架，將近期臨床進展、監管里程碑和商業性發展置於一個連貫的策略敘事框架內。本入門指南整合了從聯合治療免疫力缺乏療法到現代重點領域（例如長效製劑、簡化治療方法和差異化護理路徑）的科學發展軌跡，同時也探討了擴大公平獲取途徑和降低發病率等仍然至關重要的公共衛生抗逆轉錄病毒。

本文探討了由科學創新、監管變革以及患者和支付方期望的演變所推動的愛滋病治療領域的主要變革性變化。

在科學突破、監管進步和患者期望不斷變化等因素的推動下，愛滋病治療領域正經歷著一場變革性的轉變，這些因素共同重塑了標準治療方案和商業性機會。整合酶抑制劑和長效注射劑等創新療法透過提高療效、耐受性和依從性，正在改變治療模式，從而鼓勵醫生和患者優先選擇治療方法。

本分析探討了 2025 年美國關稅措施將如何重塑整個 HIV 治療生態系統的供應鏈、籌資策略和製造決策。

美國2025年實施的關稅和貿易措施對愛滋病治療藥物的整個價值鏈產生了複雜的影響，波及籌資策略、製造地選擇以及跨境供應的可靠性。製造商和經銷商面臨利潤率和物流成本結構的更大壓力，促使許多企業重新評估籌資策略，並探索近岸外包和雙重採購機制，以降低關稅變化帶來的風險。因此，採購負責人和醫療系統在合約談判中面臨更大的複雜性，必須考慮到前置作業時間帶來的不確定額外成本和更長的交貨週期。

整合藥物類別、給藥方法、治療線、給藥途徑、患者類型和分銷管道等關鍵細分洞察，以進行策略性澄清。

精細化的細分觀點能夠清楚地展現臨床、商業和營運重點的交會點，為跨產品系列和通路策略的策略決策提供系統性的基礎。按藥物類別分類，涵蓋了進入抑制劑、整合酶鏈轉移抑制劑、非核苷類逆轉錄酶抑制劑、核苷類逆轉錄酶抑制劑和蛋白酶抑制劑。進入抑制劑以恩夫韋地和馬拉維羅為例進行分析，而整合酶抑制劑則以比克替拉韋、多替拉韋、埃爾維格拉韋和拉替拉韋為例進行分析。透過依非韋倫、依曲韋林、奈韋拉平、利匹韋林檢驗非核苷類逆轉錄酶抑制劑，透過阿巴卡韋、恩曲他濱、拉米夫定、替諾福韋、齊多夫定來分析核苷類逆轉錄酶抑制劑，透過阿扎那韋、達蘆那韋、福沙那韋、洛那韋抑制劑、洛那韋。

美洲、歐洲、中東和非洲以及亞太地區的主要區域趨勢正在塑造准入途徑、法規和商業化策略。

區域趨勢對愛滋病治療藥物的臨床應用、取得途徑和商業策略有著顯著影響，每個地區在監管、支付者和供應鏈方面都有其獨特的考量。在美洲，成熟的法規結構、完善的治療指南以及與集中支付方強大的議價能力，推動了對差異化治療方法和基於療效的合約的需求。同時，供應鏈的複雜性使得強大的經銷夥伴和病患支援計畫至關重要。

這是一份公司層面的策略洞察報告，詳細介紹了原廠藥生產商、生物技術公司、非專利藥生產商和生產合作夥伴如何塑造 HIV 治療市場的競爭格局和市場准入。

主要企業和策略性參與企業透過對研發管線的投資、夥伴關係模式和生產規模，在塑造愛滋病治療生態系統中扮演不同的角色。原廠藥廠持續投資於下一代分子、長效平台和新型給藥系統，利用臨床差異化優勢力求佔據高階市場地位，同時制定生命週期策略以應對非專利的市場佔有率侵蝕。同時，生技公司正透過敏捷地開發First-in-Class的作用機制和生物製藥方法來推動創新，並經常與主要參與者合作，以利用其研發專長和商業性影響力。

為行業領導者提供切實可行的建議，以促進治療方法創新與具有韌性的供應鏈、支付方參與和以患者為中心的服務模式的融合。

產業領導者應優先考慮一系列切實可行的策略，將科學創新與供應鏈韌性、支付方合作以及以患者為中心的服務模式相結合，從而在改善公共衛生結果的同時創造價值。首先，企業應透過建立多元化的採購管道、認證替代製造商以及採取緊急庫存管理措施來增強供應鏈多元化，以應對貿易和物流中斷。其次，在投資研發長效製劑和簡化給藥方法的同時，應進行有針對性的證據研究，證明提高用藥依從性和提升醫療系統效率的益處，從而促進支付方接受並將其納入處方集。

採用綜合調查方法，結合一手訪談、二手文獻回顧和檢驗，以檢驗見解和策略意義。

本分析的調查方法結合了嚴謹的一手和二手研究手段，以確保研究結果的可靠性、有效性和可重複性。一手研究包括與各類利益相關者進行結構化訪談和定性討論，這些利益相關者包括臨床醫生、採購專業人員、支付方、關鍵意見領袖（KOL）和行業高管，旨在收集他們對臨床實踐、報銷趨勢和運營限制的真實觀點。這些對話旨在揭示影響治療選擇、獲取醫療服務的障礙以及所有相關人員策略重點的因素。

總結整合工作，強調臨床創新、支付方合作和彈性運作結構的策略協調，以改善 HIV 治療的可近性和治療效果。

總之，現代愛滋病治療格局的特點是臨床創新顯著、監管機構和支付方的期望不斷變化，以及對供應鏈韌性和公平獲取的日益重視。整合酵素抑制劑和長效藥物體現了治療進展如何改善患者的用藥依從性和體驗，而商業性現實則凸顯了製定一項平衡創新、可負擔性和可靠供應的綜合策略的必要性。因此，相關人員必須採取綜合方法，將臨床差異化與實際營運效率結合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：免疫力缺乏病毒（HIV）治療市場：依藥物類別分類

  • 入侵抑制劑
    • 恩夫維爾奇德
    • 馬拉威羅克
  • 整合酶/鏈轉移抑制劑
    • 比克替拉韋
    • 多替拉韋
    • 埃爾維特格拉維爾
    • 拉特格拉維爾
  • 非核苷類逆轉錄酶抑制劑
    • 依非韋倫
    • 依福西林
    • 奈韋拉平
    • 利匹韋林
  • 核苷類逆轉錄酶抑制劑
    • 阿巴卡韋
    • 恩曲他濱
    • 拉米夫定
    • 替諾福韋
    • 齊多夫定
  • 蛋白酶抑制劑
    • 阿扎那韋
    • 達蘆那韋
    • 福斯帕奈韋
    • 洛匹那韋

第9章：人類免疫力缺乏病毒（HIV）治療市場：依治療方法

  • 組合方案
  • 單藥治療方案

第10章：免疫力缺乏病毒（HIV）治療市場：依治療階段分類

  • 一線治療
  • 補救性治療
  • 二線治療

第11章：免疫力缺乏病毒（HIV）治療市場：依給藥途徑分類

  • 注射藥物
  • 口服

第12章：免疫力缺乏病毒（HIV）治療市場：依患者類型分類

  • 成人
  • 兒童

第13章：人類免疫力缺乏病毒（HIV）治療藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章：免疫力缺乏病毒（HIV）治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：免疫力缺乏病毒（HIV）治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 人類免疫力缺乏病毒（HIV）治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 美國：人類免疫力缺乏病毒（HIV）治療市場

第18章 中國：人類免疫力缺乏病毒（HIV）治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Janssen Pharmaceutica NV
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • ViiV Healthcare Limited
  • Zydus Lifesciences Limited
Product Code: MRR-ED54C46E8CF6

The Human Immunodeficiency Virus Therapeutics Market was valued at USD 21.23 billion in 2025 and is projected to grow to USD 22.23 billion in 2026, with a CAGR of 4.71%, reaching USD 29.32 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 21.23 billion
Estimated Year [2026] USD 22.23 billion
Forecast Year [2032] USD 29.32 billion
CAGR (%) 4.71%

Introductory framing that contextualizes clinical advances, policy developments, and stakeholder imperatives shaping contemporary HIV therapeutic strategies

The evolving landscape of human immunodeficiency virus therapeutics demands an introductory framework that situates recent clinical advances, regulatory milestones, and commercial dynamics within a coherent strategic narrative. This introduction synthesizes the scientific trajectory from combination antiretroviral therapy to contemporary priorities such as long-acting formulations, simplified regimens, and differentiated care pathways, while also acknowledging the persistent public health imperative to expand equitable access and reduce morbidity.

Moreover, the introduction clarifies stakeholder perspectives across clinicians, payers, manufacturers, and patient advocates, highlighting how clinical efficacy, tolerability, and real-world adherence shape treatment selection and commercialization. It delineates the interplay between therapeutic innovation and health system capacity, emphasizing how shifts in administration modality and regimen complexity have direct implications for supply chains and distribution strategies. Consequently, this framing sets expectations for deeper sections that analyze regulatory trends, competitive dynamics, and market segmentation, thereby equipping decision-makers with the context needed to prioritize investment, policy engagement, and strategic partnerships.

Examining the major transformative shifts in HIV therapeutics driven by scientific innovation, regulatory change, and evolving patient and payer expectations

The therapeutic landscape for HIV has undergone transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing patient expectations, which together are redefining standard-of-care and commercial opportunity. Innovations such as integrase inhibitors and long-acting injectable formulations have altered treatment paradigms by improving potency, tolerability, and adherence profiles, thereby encouraging prescribers and patients to prioritize regimens that reduce pill burden and support sustained viral suppression.

Concurrently, regulatory pathways have adapted to accommodate faster approvals for formulations that demonstrate meaningful improvements in adherence and quality of life, while payers and procurement agencies are increasingly emphasizing total cost of care and outcomes-based contracting. Moreover, the expanded focus on differentiated care models and decentralized delivery is reshaping distribution channels, as community-led programs and online pharmacies amplify reach. As a result, pharmaceutical companies must balance innovation with affordability and supply reliability, integrating patient-centered clinical development with pragmatic commercialization strategies to capture value while advancing public health goals.

Analyzing how the 2025 United States tariff measures reshaped supply chains, procurement strategies, and manufacturing decisions across the HIV therapeutics ecosystem

The imposition of tariffs and trade measures by the United States in 2025 introduced a complex set of effects across the HIV therapeutic value chain, influencing procurement strategies, manufacturing location decisions, and cross-border supply reliability. Manufacturers and distributors experienced increased pressure on margins and logistical cost structures, prompting many to reassess sourcing strategies and to explore nearshoring or dual-sourcing arrangements to mitigate exposure to tariff volatility. Consequently, procurement officers and health systems faced heightened complexity when negotiating contracts that now needed to account for contingent tariff-related surcharges and longer lead times.

Moreover, tariffs altered the calculus for investment in domestic production capacity and strategic stockpiling, accelerating conversations around resilience and self-sufficiency for critical antiretrovirals and key active pharmaceutical ingredients. In response, several stakeholders intensified collaboration with contract manufacturers and exporters in tariff-exempt jurisdictions, while others accelerated investments in regulatory harmonization to streamline cross-border distribution. These adaptive measures, taken together, underscore the strategic necessity of supply chain agility and informed policy engagement to preserve patient access and maintain program continuity amid trade-induced disruption.

Critical segmentation insights that integrate drug class, regimen type, therapy line, administration mode, patient type, and distribution channel for strategic clarity

A granular segmentation lens clarifies where clinical, commercial, and operational priorities converge, providing a structured basis for strategic decision-making across product portfolios and channel strategies. Based on drug class, analysis spans Entry Inhibitors, Integrase Strand Transfer Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors, with Entry Inhibitors examined through Enfuvirtide and Maraviroc; Integrase inhibitors covered via Bictegravir, Dolutegravir, Elvitegravir, and Raltegravir; Non-Nucleoside reverse transcriptase inhibitors considered through Efavirenz, Etravirine, Nevirapine, and Rilpivirine; Nucleoside reverse transcriptase inhibitors analyzed including Abacavir, Emtricitabine, Lamivudine, Tenofovir, and Zidovudine; and Protease Inhibitors evaluated through Atazanavir, Darunavir, Fosamprenavir, and Lopinavir.

Based on regimen type, the landscape distinguishes between Multi Tablet Regimen and Single Tablet Regimen, recognizing that simplification of dosing remains a central driver of adherence and therapeutic persistence. Based on therapy line, segmentation includes First Line, Salvage Therapy, and Second Line, which informs development priorities for agents intended for treatment-experienced populations or for use where resistance patterns constrain options. Based on mode of administration, the analysis contrasts Injectable and Oral modalities, reflecting the commercial and operational ramifications of long-acting injectables versus daily oral therapies. Based on patient type, differentiation between Adult and Pediatric populations highlights formulation needs, palatability, and dosing considerations that influence pediatric program design. Finally, based on distribution channel, the framework examines Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy dynamics, recognizing that channel-specific procurement, reimbursement, and adherence support models materially affect uptake and access.

Key regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access pathways, regulation, and commercialization strategies

Regional dynamics materially influence clinical adoption, access pathways, and commercial strategies for HIV therapeutics, with each geography presenting distinct regulatory, payer, and delivery considerations. In the Americas, mature regulatory frameworks, established treatment guidelines, and concentrated payer negotiation leverage drive demand for differentiated regimens and outcomes-based contracting, while supply chain complexity necessitates robust distribution partnerships and patient support programs.

Across Europe, Middle East & Africa, heterogeneity in regulatory capacity, procurement models, and health system financing shapes varied adoption patterns; high-income markets prioritize innovation and formulary placement, whereas middle- and low-income settings emphasize affordability, generic competition, and procurement through pooled purchasing mechanisms. In Asia-Pacific, a mix of large domestic manufacturers, progressive regulatory reform in certain jurisdictions, and rapidly evolving private and public payer arrangements create opportunities for localized manufacturing, tiered pricing strategies, and digital health-enabled adherence interventions. Taken together, these regional distinctions underscore the need for tailored commercialization and access strategies that reflect regulatory timelines, procurement structures, and patient population characteristics.

Strategic company-level insights detailing how originators, biotech innovators, generics, and manufacturing partners shape competition and access in HIV therapeutics

Leading companies and strategic entrants each play distinct roles in shaping the HIV therapeutics ecosystem through pipeline investment, partnership models, and manufacturing scale. Originator pharmaceutical firms continue to invest in next-generation molecules, long-acting platforms, and novel delivery systems, leveraging clinical differentiation to pursue premium placements while managing lifecycle strategies against generic erosion. At the same time, biotechnology firms drive innovation with nimble development of first-in-class mechanisms and biologic approaches, frequently collaborating with larger partners to access development expertise and commercial reach.

Generic manufacturers and contract development and manufacturing organizations serve as critical pillars for affordability and supply resilience, particularly in regions where price sensitivity and centralized procurement dominate. Strategic partnerships, licensing agreements, and targeted acquisitions have become common tactics for companies seeking to quickly expand therapeutic breadth or to secure manufacturing capacity. In parallel, technology and digital health companies are increasingly adjacent players, offering adherence support, remote monitoring, and patient engagement solutions that enhance the real-world effectiveness of therapeutics. Together, these actors create an ecosystem where commercial success depends on scientific differentiation, strategic alliances, and the ability to operationalize distribution and patient support at scale.

Practical and actionable recommendations for industry leaders to align therapeutic innovation with resilient supply chains, payer engagement, and patient-centered delivery

Industry leaders should prioritize a suite of actionable strategies that align scientific innovation with supply resilience, payer engagement, and patient-centered delivery models to capture value while improving public health outcomes. First, firms ought to strengthen supply chain diversification by establishing multiple sourcing lanes, qualifying alternative manufacturers, and incorporating contingency inventory practices to guard against trade and logistics disruptions. Second, investment in long-acting formulations and simplified regimens should be paired with targeted evidence generation that demonstrates adherence benefits and health system efficiencies, thereby easing payer acceptance and formulary uptake.

Furthermore, organizations need to actively engage payers and procurement bodies early in development to design value propositions that speak to total cost of care, adherence outcomes, and real-world effectiveness. Concurrently, advancing pediatric-friendly formulations and pragmatic administration models will address persistent access gaps. Companies should also leverage partnerships for local manufacturing or technology transfer where appropriate, enabling tiered pricing and faster market entry. Finally, integrating digital adherence tools and patient support programs into commercialization plans will strengthen therapy persistence and outcomes. These recommendations collectively offer a roadmap for aligning innovation with pragmatic execution across clinical, regulatory, and commercial domains.

Comprehensive research methodology that integrates primary interviews, secondary literature review, and triangulation to validate insights and strategic implications

The research methodology underpinning this analysis combines rigorous primary and secondary approaches to ensure reliability, relevance, and reproducibility of insights. Primary research involved structured interviews and qualitative discussions with a cross-section of clinicians, procurement specialists, payers, key opinion leaders, and industry executives, enabling the capture of real-world perspectives on clinical practice, reimbursement dynamics, and operational constraints. These conversations were designed to surface drivers of treatment choice, barriers to access, and strategic priorities across stakeholder groups.

Secondary research complemented primary inputs through systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to validate clinical and regulatory trends. Data triangulation techniques were applied to reconcile divergent sources and to strengthen confidence in thematic conclusions. Analytical rigor was further enhanced via scenario analysis and sensitivity checks to assess the robustness of strategic implications under varying assumptions. Ethical considerations, including the protection of participant confidentiality and avoidance of commercial bias, were integral to the research process, and limitations related to regional data granularity and rapidly evolving clinical evidence were transparently acknowledged.

Conclusive synthesis emphasizing strategic alignment of clinical innovation, payer engagement, and resilient operations to advance HIV therapeutic access and outcomes

In conclusion, the contemporary HIV therapeutics environment is characterized by meaningful clinical innovation, shifting regulatory and payer expectations, and a heightened focus on supply chain resilience and equitable access. Integrase inhibitors and long-acting modalities exemplify how therapeutic advances can translate into improved adherence and patient experience, while the commercial reality underscores the need for holistic strategies that reconcile innovation with affordability and distribution reliability. Consequently, stakeholders must adopt integrated approaches that bridge clinical differentiation with pragmatic operational execution.

Looking ahead, organizations that successfully align robust evidence generation, proactive payer engagement, and diversified manufacturing and distribution capabilities will be best positioned to deliver both commercial value and public health impact. Continued collaboration across industry, payers, providers, and community organizations will remain essential to translate therapeutic advances into durable improvements in treatment outcomes and access. Ultimately, strategic agility, evidence-based value propositions, and patient-centered delivery models will determine which programs attain sustainable success in this dynamic therapeutic arena.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Immunodeficiency Virus Therapeutics Market, by Drug Class

  • 8.1. Entry Inhibitors
    • 8.1.1. Enfuvirtide
    • 8.1.2. Maraviroc
  • 8.2. Integrase Strand Transfer Inhibitors
    • 8.2.1. Bictegravir
    • 8.2.2. Dolutegravir
    • 8.2.3. Elvitegravir
    • 8.2.4. Raltegravir
  • 8.3. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 8.3.1. Efavirenz
    • 8.3.2. Etravirine
    • 8.3.3. Nevirapine
    • 8.3.4. Rilpivirine
  • 8.4. Nucleoside Reverse Transcriptase Inhibitors
    • 8.4.1. Abacavir
    • 8.4.2. Emtricitabine
    • 8.4.3. Lamivudine
    • 8.4.4. Tenofovir
    • 8.4.5. Zidovudine
  • 8.5. Protease Inhibitors
    • 8.5.1. Atazanavir
    • 8.5.2. Darunavir
    • 8.5.3. Fosamprenavir
    • 8.5.4. Lopinavir

9. Human Immunodeficiency Virus Therapeutics Market, by Regimen Type

  • 9.1. Multi Tablet Regimen
  • 9.2. Single Tablet Regimen

10. Human Immunodeficiency Virus Therapeutics Market, by Therapy Line

  • 10.1. First Line
  • 10.2. Salvage Therapy
  • 10.3. Second Line

11. Human Immunodeficiency Virus Therapeutics Market, by Mode Of Administration

  • 11.1. Injectable
  • 11.2. Oral

12. Human Immunodeficiency Virus Therapeutics Market, by Patient Type

  • 12.1. Adult
  • 12.2. Pediatric

13. Human Immunodeficiency Virus Therapeutics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Human Immunodeficiency Virus Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Human Immunodeficiency Virus Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Human Immunodeficiency Virus Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Human Immunodeficiency Virus Therapeutics Market

18. China Human Immunodeficiency Virus Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Aspen Pharmacare Holdings Limited
  • 19.7. Aurobindo Pharma Limited
  • 19.8. Boehringer Ingelheim International GmbH
  • 19.9. Bristol-Myers Squibb Company
  • 19.10. Cipla Limited
  • 19.11. Genentech, Inc.
  • 19.12. Gilead Sciences, Inc.
  • 19.13. GlaxoSmithKline plc
  • 19.14. Hetero Labs Limited
  • 19.15. Janssen Pharmaceutica NV
  • 19.16. Merck & Co., Inc.
  • 19.17. Pfizer Inc.
  • 19.18. Shionogi & Co., Ltd.
  • 19.19. Sun Pharmaceutical Industries Ltd.
  • 19.20. Teva Pharmaceutical Industries Ltd.
  • 19.21. Viatris Inc.
  • 19.22. ViiV Healthcare Limited
  • 19.23. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 235. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARK